Trial · NCT00508924

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

NCT00508924, Phase 2, Completed, Tanabe Pharma Corporation; results first posted 2012-12-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI). Trials, record NCT00508924. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00508924

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
NCT number: NCT00508924
Status: Completed
Phases: Phase 2
Enrollment: 140 participants, actual
Lead sponsor: Tanabe Pharma Corporation
Conditions: Coronary Artery Disease, Angina, Unstable
Interventions: Argatroban, Argatroban, Argatroban, Heparin
First posted: 2007-07-30
Last updated: 2026-01-06
Results first posted: 2012-12-05

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.	5 - 10 min after initial bolus
Primary	Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.	30 Days	Composite end point (a): all cause death, myocardial infarction and urgent revascularization at Day30 Composite end point (b): all cause death, myocardial infarction and urgent revascularization at Day30 as well as major bleeding events during hospital stay

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.	5 - 10 min after initial bolus		second	MEDIAN
PRIMARY	Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.	30 Days		participants	NUMBER

Source ClinicalTrials.gov

Results by group28

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.	ARG250		301.0	Inter-Quartile Range 262.8 to 330.0	second
Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.	ARG300		330.0	Inter-Quartile Range 270.0 to 365.0	second
Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.	ARG350		354.0	Inter-Quartile Range 307.0 to 391.0	second
Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.	Heparin		237.5	Inter-Quartile Range 198.0 to 284.0	second
Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.	ARG250	Composite end point (a)	1		participants
Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.	ARG300	Composite end point (a)	0		participants
Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.	ARG350	Composite end point (a)	1		participants
Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.	Heparin	Composite end point (a)	1		participants
Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.	ARG250	Composite end point (b)	1		participants
Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.	ARG300	Composite end point (b)	0		participants

1 to 10 of 28Source ClinicalTrials.gov

See all 28 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	ARG250	36
Overall Study	STARTED	ARG300	38
Overall Study	STARTED	ARG350	32
Overall Study	STARTED	Heparin	34
Overall Study	COMPLETED	ARG250	36
Overall Study	COMPLETED	ARG300	38
Overall Study	COMPLETED	ARG350	31
Overall Study	COMPLETED	Heparin	33
Overall Study	NOT COMPLETED	ARG250	0
Overall Study	NOT COMPLETED	ARG300	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events196

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Angina pectoris	Cardiac disorders	ARG250	2	36
other	Angina pectoris	Cardiac disorders	ARG300	3	38
other	Angina pectoris	Cardiac disorders	ARG350	4	32
other	Angina pectoris	Cardiac disorders	Heparin	4	34
other	Bradycardia	Cardiac disorders	ARG250	0	36
other	Bradycardia	Cardiac disorders	ARG300	0	38
other	Bradycardia	Cardiac disorders	ARG350	0	32
other	Bradycardia	Cardiac disorders	Heparin	3	34
other	Sinus bradycardia	Cardiac disorders	ARG250	0	36
other	Sinus bradycardia	Cardiac disorders	ARG300	0	38

1 to 10 of 196Source ClinicalTrials.gov

See all 196 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	ARG250
Total, all-cause mortality	ARG300
Total, all-cause mortality	ARG350
Total, all-cause mortality	Heparin
Total, other adverse events	ARG250	22	36
Total, other adverse events	ARG300	25	38
Total, other adverse events	ARG350	23	32
Total, other adverse events	Heparin	27	34
Total, serious adverse events	ARG250	4	36
Total, serious adverse events	ARG300	5	38

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
20226548	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00508924

GET https://conductscience.org/api/trials/v1/NCT00508924/results?page=2

API reference For AI assistants